Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
OwnerAlbert Sattin, Albert E. Pekary +1inventors
InventorsAlbert Sattin, Albert E. Pekary, Robert L. Lloyd
Life of this patent
Estimating the term…
Abstract
A tri-peptide drug for treatment of neurological and neurobehavioral disorders of a mammal, such drug being derived from the following formula: pGlu-X-Pro-NH2, wherein the internal amino acid (X) is a non-histadine amino acid. Methods of treatment of neurological disorders using the tri-peptide, including as an adjunct, synergist or stand-alone therapy, in oral, parenteral, intranasal, transcutaneous, or rectal forms.
Claims6
A method of treatment of depression, schizophrenia or affective disorders in a mammal comprising the following steps:
- a) providing a therapeutically effective amount of a composition comprising a peptide or pharmaceutically acceptable salt thereof of the formula pGlu-Glu-Pro-NH2;
- b) administering the composition to the mammal.
A method of treatment of depression, schizophrenia or affective disorders in a mammal comprising the following steps:
- a) providing a therapeutically effective amount of a composition comprising a peptide or pharmaceutically acceptable salt thereof of the formula pGlu-Phe-Pro-NH2;
- b) administering the composition to the mammal.
Dependencies are inferred from the claim text.